Molecular dynamics simulations of asymmetric heterodimers of HER1/HER2 complexes

被引:0
|
作者
Chonticha Suwattanasophon
Napat Songtawee
Peter Wolschann
Kiattawee Choowongkomon
机构
[1] Kasertsart University,Department of Biochemistry, Faculty of Science
[2] Kasetsart University,Center for Advanced Studies in Tropical Natural Resources, National Research University
[3] Mahidol University,Kasetsart University
[4] University of Vienna,Department of Clinical Chemistry, Faculty of Medical Technology
[5] University of Vienna,Institute for Theoretical Chemistry
来源
关键词
HER family; Molecular dynamics simulation; Heterodimer; HER1; ErbB2;
D O I
暂无
中图分类号
学科分类号
摘要
The family of human epidermal growth factor receptors (HER) is involved in tumor cell growth. Homodimerization and heterodimerization of the HER family are important for activation of these receptors. The structures of homodimer conformation are well characterized, while the structures of heterodimer conformations, especially between HER1 and HER2, are not completely understood. In this study, two models of possible asymmetric HER1/HER2 kinase domains were built. Molecular dynamics simulations and molecular mechanics-Poisson-Boltzmann surface area (MM-PBSA) methods were applied to examine the possibility of these two-heterodimer interactions. From our results, it could be concluded that the HER2 kinase domain prefers to serve as the receiver rather than the activator. Key binding residues of this dimer complex at N lobe of HER2 is ALA683 and at C lobe of HER1 are GLU914, GLU917, and ASP930. This study will be useful in allowing us to predict and be able to control activity of this enzyme in disease in the future.
引用
收藏
相关论文
共 50 条
  • [21] Active immunotherapy based on HER1 and HER2 oncogenes as an alternative strategy to treat cancer patients
    Sanchez, B.
    Gonzalez, N.
    Bergado, G.
    Hernandez, D. R.
    Mesa, M.
    Fernandez, L. E.
    Mazorra, Z.
    Lavastida, A.
    Popa, X.
    Aira, L. E.
    Casaco, A.
    Caballero, I.
    Joaquin, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 55 : S24 - S25
  • [22] Cytogenetic analysis of Her1/EGFR, Her2/neu, Her3, and hEr4 receptor tyrosine kinases in breast cancer
    Sassen, A.
    Rochon, J.
    Wild, P.
    Hartmann, A.
    Hofstaedter, F.
    Schwarz, S.
    Brockhoff, G.
    CYTOMETRY PART A, 2007, 71A (07) : 515 - 515
  • [23] Lapatinib, a Dual HER1/HER2 Tyrosine Kinase Inhibitor, Augments Basal Cleavage of HER2 Extracellular Domain (ECD) to Inhibit HER2-Driven Cancer Cell Growth
    Vazquez-Martin, Alejandro
    Oliveras-Ferraros, Cristina
    Cufi, Silvia
    del Barco, Sonia
    Martin-Castillo, Begona
    Menendez, Javier A.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2011, 226 (01) : 52 - 57
  • [24] FGFR1 and HER1 or HER2 co-amplification in breast cancer indicate poor prognosis
    Chen, Shinan
    Qiu, Yan
    Guo, Peng
    Pu, Tianjie
    Feng, Ye
    Bu, Hong
    ONCOLOGY LETTERS, 2018, 15 (06) : 8206 - 8214
  • [25] HER1, HER2, HER3 and HER4-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer
    Bachmann, C.
    Brockhoff, G.
    Grischke, E.
    Staebler, A.
    Schittenhelm, J.
    Wallwiener, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 17 - 17
  • [26] Analysis of HER1 and HER2 status in CNS metastases from patients (pts) with breast carcinoma (BC)
    Viale, G.
    Del Curto, B.
    Orvieto, E.
    Maiorano, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] BMS-599626: A novel dual inhibitor of HER1 and HER2 protein tyrosine kinases.
    Gavai, AV
    Fink, BE
    Tokarski, JS
    Fairfax, D
    Martin, G
    Grubb, L
    Fu, Z
    Kim, SH
    Leavitt, K
    Mastalerz, H
    Mitt, T
    Hunt, JT
    Kadow, JF
    Du, KR
    Han, WC
    Norris, D
    Goyal, B
    Vyas, DM
    Yu, C
    Oppenheimer, S
    Zhang, HJ
    Lee, FY
    Wong, TW
    Vite, GD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U108 - U108
  • [28] The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
    Memon, A. A.
    Sorensen, B. S.
    Meldgaard, P.
    Fokdal, L.
    Thykjaer, T.
    Nexo, E.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1703 - 1709
  • [29] Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2
    Zhang, K
    Sun, JL
    Liu, NL
    Wen, DZ
    Chang, D
    Thomason, A
    Yoshinaga, SK
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (07) : 3884 - 3890
  • [30] The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
    A A Memon
    B S Sorensen
    P Meldgaard
    L Fokdal
    T Thykjaer
    E Nexo
    British Journal of Cancer, 2006, 94 : 1703 - 1709